NASDAQ:BEAM Beam Therapeutics (BEAM) Stock Price, News & Analysis $20.86 -0.08 (-0.38%) Closing price 11/20/2026 03:58 PM EasternExtended Trading$21.36 +0.50 (+2.42%) As of 11/20/2026 07:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Beam Therapeutics Stock (NASDAQ:BEAM) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Beam Therapeutics alerts:Sign Up Key Stats Today's Range$20.54▼$22.1050-Day Range$20.65▼$28.8452-Week Range$20.39▼$38.26Volume3.88 million shsAverage Volume2.48 million shsMarket Capitalization$2.16 billionP/E RatioN/ADividend YieldN/APrice Target$47.64Consensus RatingModerate Buy Company Overview Beam Therapeutics is a biotechnology company developing genetic medicines using base editing, a form of gene editing designed to make precise changes to DNA. Its platform includes base-editing technologies and delivery systems intended to address diseases by altering the genetic instructions involved in their development. The company’s research and development programs include potential treatments for genetic diseases, including sickle cell disease. Its work spans medicines made by editing a patient’s cells outside the body as well as approaches intended to deliver gene editing directly to cells in the body. Beam is a clinical-stage company focused on developing its programs rather than selling approved medicines. Founded in 2017, Beam is headquartered in Cambridge, Massachusetts. John Evans, a company co-founder, serves as its chief executive officer.AI Generated. May Contain Errors. Read More Beam Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks47th Percentile Overall ScoreBEAM MarketRank™: 2.35249095463 of 5 starsBeam Therapeutics scored higher than 47% of companies evaluated by MarketBeat, and ranked 506th out of 845 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingBeam Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 1 strong buy rating, 8 buy ratings, 2 hold ratings, and 1 sell rating.Upside PotentialBeam Therapeutics has a consensus price target of $47.64, representing about 128.4% upside from its current price of $20.86.Amount of Analyst CoverageBeam Therapeutics has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Beam Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Beam Therapeutics are expected to decrease in the coming year, from ($4.65) to ($5.15) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Beam Therapeutics is -20.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Beam Therapeutics is -20.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioBeam Therapeutics has a P/B Ratio of 2.27. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted26.20% of the float of Beam Therapeutics has been sold short.Short Interest Ratio / Days to CoverBeam Therapeutics has a short interest ratio ("days to cover") of 13.69, which indicates bearish sentiment.Change versus previous monthShort interest in Beam Therapeutics has recently decreased by 0.61%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldBeam Therapeutics does not currently pay a dividend.Dividend GrowthBeam Therapeutics does not have a long track record of dividend growth. News and Social Media2.1 / 5News Sentiment0.31 News SentimentBeam Therapeutics has a news sentiment score of 0.31. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.41 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Beam Therapeutics this week, compared to 6 articles on an average week.Search Interest13 people have searched for BEAM on MarketBeat in the last 30 days. This is an increase of 30% compared to the previous 30 days.MarketBeat FollowsOnly 6 people have added Beam Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership1.6 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Beam Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $589,250.00 in company stock.Percentage Held by Insiders3.80% of the stock of Beam Therapeutics is held by insiders.Percentage Held by Institutions99.68% of the stock of Beam Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Beam Therapeutics' insider trading history. Receive BEAM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Beam Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. BEAM Stock News HeadlinesPositive Trial Results Could Be A Big Moment For Beam Therapeutics (BEAM)November 19 at 3:17 AM | finance.yahoo.comTranscript : Beam Therapeutics Inc. Presents at UBS Global Biopharma Conference 2026, Nov-17-2026 02:00 PMNovember 17, 2026 | marketscreener.comMYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time through a temporary download link. He plans to charge for it soon. Download your copy now and lock it in at no cost, regardless of future pricing.November 21 at 1:00 AM | Profits Run (Ad)Beam Therapeutics Inc. (BEAM) Presents at UBS Global Biopharma Conference 2026 Prepared Remarks TranscriptNovember 17, 2026 | seekingalpha.comBeam Therapeutics (NASDAQ:BEAM) Price Target Raised to $33.00November 14, 2026 | americanbankingnews.comBeam Therapeutics: Market Selling Promising Data Readouts Doesn't Add UpNovember 12, 2026 | seekingalpha.comResearch Analysts Offer Predictions for BEAM FY2026 EarningsNovember 12, 2026 | americanbankingnews.comBeam Therapeutics (BEAM) Clears A Key Trial As The Undervalued Case Faces A TestNovember 10, 2026 | finance.yahoo.comSee More Headlines BEAM Stock Analysis - Frequently Asked Questions How have BEAM shares performed this year? Beam Therapeutics' stock was trading at $27.72 at the start of the year. Since then, BEAM stock has decreased by 24.7% and is now trading at $20.8610. How were Beam Therapeutics' earnings last quarter? Beam Therapeutics Inc. (NASDAQ:BEAM) released its earnings results on Tuesday, November, 3rd. The company reported ($1.28) EPS for the quarter, missing analysts' consensus estimates of ($1.17) by $0.11. The company's quarterly revenue was down 96.8% on a year-over-year basis. Does Beam Therapeutics have any subsidiaries? The following companies are subsidiaries of Beam Therapeutics: Blink Therapeutics Inc.. When did Beam Therapeutics IPO? Beam Therapeutics (BEAM) raised $169 million in an initial public offering on Thursday, February 6th 2020. The company issued 10,588,236 shares at $15.00-$17.00 per share. J.P. Morgan, Jefferies and Barclays acted as the underwriters for the IPO and Wedbush PacGrow was co-manager. Who are Beam Therapeutics' major shareholders? Top institutional investors of Beam Therapeutics include State Street Corp (5.72%), Sumitomo Mitsui Trust Group Inc. (3.24%), Goldman Sachs Group Inc. (1.30%) and Marshall Wace LLP (0.47%). Insiders that own company stock include John M Evans, Fmr Llc, Giuseppe Ciaramella, Christine Bellon, Amy Simon, Terry-Ann Burrell and Bethany J Cavanagh. View institutional ownership trends. How do I buy shares of Beam Therapeutics? Shares of BEAM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Beam Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Beam Therapeutics investors own include CRISPR Therapeutics (CRSP), NVIDIA (NVDA), Advanced Micro Devices (AMD), Palantir Technologies (PLTR), Tesla (TSLA), Intellia Therapeutics (NTLA) and Micron Technology (MU). Company Calendar Last Earnings11/03/2026Today11/21/20269th Annual Evercore ISI HealthCONx Conference12/02/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (1w+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 For the last 9 days, BEAM's financial health has been in the Yellow zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:BEAM CIK1745999 Webwww.beamtx.com Phone857-327-8775FaxN/AEmployees540Year Founded2017Price Target and Rating Average Price Target for Beam Therapeutics$47.64 High Price Target$80.00 Low Price Target$26.00 Potential Upside/Downside+128.4%Consensus RatingModerate Buy Rating Score (0-4)2.75 Research Coverage12 Analysts Profitability EPS (Trailing Twelve Months)($1.04) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$79.99 million Net Margins-73.04% Pretax Margin-73.89% Return on Equity-32.76% Return on Assets-25.80% Debt Debt-to-Equity Ratio0.11 Current Ratio13.01 Quick Ratio13.00 Sales & Book Value Annual Sales$139.74 million Price / Sales15.45 Cash FlowN/A Price / Cash FlowN/A Book Value$9.20 per share Price / Book2.27Miscellaneous Outstanding Shares103,500,000Free Float99,563,000Market Cap$2.16 billion OptionableOptionable Beta2.23 Social Links 7 Energy Stocks to Buy and Hold ForeverOil still powers the global economy, but AI is reshaping the energy opportunity. Discover seven stocks spanning traditional energy, infrastructure, and next-generation power.Get This Free Report This page (NASDAQ:BEAM) was last updated on 11/20/2026 by MarketBeat.com Staff. From Our PartnersSeven bucks, yours for life: my Black Friday indicator dealBase Camp Trading's Thomas Wood is giving away his proprietary Snapback Indicator for just $7 this Black Frida...Base Camp Trading | SponsoredToday's free pick (on me)Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one l...Behind the Markets | SponsoredYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | Sponsored432 miles southeast of Washington, DC…Spruce Pine, North Carolina, a town of just over 2,000 people, has supplied a material to every major chip mak...Wall Street Watchdogs | SponsoredBeyond NVDA: The World’s Next #1 Company?This small-cap trades in an overlooked corner of the market, with a market cap more than 600X smaller than Nvi...Banyan Hill Publishing | SponsoredCFA: Bank of America Said THISOn January 24th, 2022, Bank of America told Bloomberg something that should terrify every American with a savi...Decentralized Masters | SponsoredMy public warning after 55 years of watching the marketsDr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each war...Weiss Ratings | SponsoredThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Beam Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Beam Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.